Biotechnology company 4basebio PLC (AIM: 4BB) announced on Monday that a global Tier 1 pharmaceutical partner has commenced dosing patients in a US Phase I/II clinical trial using an mRNA therapy developed with 4basebio's proprietary opDNA template, following FDA Investigational New Drug (IND) approval. The supply agreement for the opDNA template was signed in April 2024.

The opDNA platform supports mRNA in vitro transcription processes, offering significant cost, purity and time advantages over conventional plasmid DNA. The milestone follows 4basebio's GMP certification by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its late-phase manufacturing facility in April 2025, reinforcing its position as a trusted synthetic DNA supplier to the global biopharma industry.

4basebio's synthetic DNA technology enables scalable, cell-free production, eliminating contamination risks and accelerating development of cell and gene therapies, vaccines and genetic medicines. The company aims to establish itself as a leader in synthetic DNA and non-viral delivery technologies that advance next-generation therapies across oncology, infectious disease and rare disorders.